SLCO1B1 and Myalgia: It has been suggested that the maximum dose of simvastatin, pitavastatin, and atorvastatin should be reduced by fourfold in individuals who are CC homozygotes based on pharmacokinetic calculations.33 Interestingly, a recent small randomized trial (n = 159) of patients not on statins because of prior myalgia attributed to a statin showed that providing information on the SLCO1B1 genotype improved statin reinitiation and low‐density lipoprotein‐cholesterol lowering, but not adherence, when compared with the usual care arm.34